Literature DB >> 16839352

On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells.

R S Fernandes1, C Kirszberg, V M Rumjanek, R Q Monteiro.   

Abstract

BACKGROUND: That there is a correlation between cancer and procoagulant states is well-known. C6 glioma cell line was originally induced in random-bred Wistar-Furth rats and is morphologically similar to glioblastoma multiforme, the most common aggressive glioma resistant to therapeutic interventions.
OBJECTIVES: In this study we analyzed the molecular mechanisms responsible for the highly procoagulant properties of C6 glioma cells.
METHODS: The presence of tissue factor (TF) and phosphatidylserine (PS) in C6 cells was investigated by flow-cytometric and functional analyses. The assembly of extrinsic tenase, intrinsic tenase and prothrombinase complexes on these cells was studied using enzymatic assays employing plasma or purified proteins.
RESULTS: TF was identified by flow-cytometric and functional [factor (F) Xa formation in the presence of cells and FVIIa] assays. Alternatively, conversion of FX into FXa was also observed in the presence of C6 cells, FIXa and FVIIIa. This effect was both cell- and FVIIIa-dependent, being consistent with formation of the intrinsic tenase complex. C6 cells were also able to activate prothrombin in the presence of FXa and FVa, thus supporting formation of the prothrombinase complex. This ability was similar to positive controls performed with PS-containing vesicles. Accordingly, exposure of PS on C6 cells was demonstrated by flow cytometry employing specific anti-PS antibodies. In addition, annexin V, which blocks PS binding sites, inhibited FX and prothrombin conversion by their respective C6-assembled activating complexes.
CONCLUSION: C6 glioma cells support all procoagulant reactions leading to robust thrombin formation. This ability results from concomitant TF exposure and from the presence of the anionic lipid PS at the outer leaflet of cell membrane. Therefore, this animal cell line may be used to explore new aspects concerning the role of blood coagulation proteins in tumor biology, especially those affecting the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16839352     DOI: 10.1111/j.1538-7836.2006.01985.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  14 in total

1.  Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.

Authors:  Andreia Da Silva de Oliveira; Luize G Lima; Andréa Mariano-Oliveira; Daniel E Machado; Luiz E Nasciutti; John F Andersen; Lars C Petersen; Ivo M B Francischetti; Robson Q Monteiro
Journal:  Thromb Res       Date:  2012-06-09       Impact factor: 3.944

2.  Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis.

Authors:  Daniella M Mizurini; Ivo M B Francischetti; John F Andersen; Robson Q Monteiro
Journal:  Thromb Haemost       Date:  2010-09-13       Impact factor: 5.249

3.  Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging.

Authors:  Vinod Kaimal; Zhengtao Chu; Yonatan Y Mahller; Brigitte Papahadjopoulos-Sternberg; Timothy P Cripe; Scott K Holland; Xiaoyang Qi
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

4.  Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?

Authors:  Ze'ev Itsekson-Hayosh; Efrat Shavit-Stein; David Last; David Goez; Dianne Daniels; Doron Bushi; Orna Gera; Zion Zibly; Yael Mardor; Joab Chapman; Sagi Harnof
Journal:  J Mol Neurosci       Date:  2015-02-19       Impact factor: 3.444

5.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

6.  Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model.

Authors:  Robson Q Monteiro; Luize G Lima; Nathália P Gonçalves; Mayara R Arruda DE Souza; Ana C Leal; Marcos A Almeida Demasi; Mari C Sogayar; Tatiana C Carneiro-Lobo
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

7.  Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Authors:  Jeffrey Wojton; Zhengtao Chu; Haritha Mathsyaraja; Walter H Meisen; Nicholas Denton; Chang-Hyuk Kwon; Lionel Ml Chow; Mary Palascak; Robert Franco; Tristan Bourdeau; Sherry Thornton; Michael C Ostrowski; Balveen Kaur; Xiaoyang Qi
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

Review 8.  Activation of blood coagulation in cancer: implications for tumour progression.

Authors:  Luize G Lima; Robson Q Monteiro
Journal:  Biosci Rep       Date:  2013-09-04       Impact factor: 3.840

9.  SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma.

Authors:  Víctor M Blanco; Richard Curry; Xiaoyang Qi
Journal:  Oncoscience       Date:  2015-02-09

10.  Leishmania amazonensis exhibits phosphatidylserine-dependent procoagulant activity, a process that is counteracted by sandfly saliva.

Authors:  Natalia Cadaxo Rochael; Luize Gonçalves Lima; Sandra Maria Pereira de Oliveira; Marcello André Barcinski; Elvira Maria Saraiva; Robson Queiroz Monteiro; Lucia Helena Pinto-da-Silva
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.